Option Chain

Agenus Inc

AGENNASDAQ · USD

7.15USD+0.71 (+11.03%)

7110

Agenus Inc (AGEN) Option Chain

Agenus Inc trades at $7.15, up 11.03%, with an IV Rank of 55.16%. This is average versus the past year, and the company carries a market cap of $291M in the Biotechnology industry. On the Nov 20, 2026 chain, the at the money $7.00 strike shows calls at $0.25 / $0.50 and puts at $0.75 / $1.55, both carrying about $0.69 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $8.00 calls, at 10 contracts, and the $9.00 puts, at 10, as of Nov 5, 2026.

Tracking the AGEN option chain helps you see every strike and expiry on Agenus Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of AGEN options activity at a glance. Use our scanner to monitor the AGEN option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For AGEN stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where AGEN options are being actively traded, and where they are not.

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody.

CALLs									PUTs
Prob. OTM %	Open Interest	Volume	Extrinsic Value	Intrinsic Value	Bid	Ask	Strike	Moneyness %	Bid	Ask	Intrinsic Value	Extrinsic Value	Volume	Open Interest	Prob. OTM %
19.18	10	0	-0.33	2.15	1.35	2.30	5.00	-22.36	—	0.30	0.00	0.30	0	4	80.82
43.79	417	0	-0.13	1.15	0.35	1.70	6.00	-6.83	—	0.60	0.00	0.60	0	95	56.21
67.30	1,191	5	0.22	0.15	0.25	0.50	7.00	+8.70	0.75	1.55	0.00	1.15	0	527	32.70
83.44	1,236	10	0.25	0.00	0.05	0.45	8.00	+24.22	1.00	2.60	0.85	0.95	0	73	16.56
92.41	469	0	0.15	0.00	0.05	0.25	9.00	+39.75	0.95	3.00	1.85	0.13	10	532	7.59

As of Nov 5, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

IndustryBiotechnology
SectorHealthcare
IV Rank55.16% Moderate
Market cap (M$)291
52 weeks high-37.54%
52 weeks low137.64%
Analyst recommendationStrong Buy
1.00
Target price$24.50
242.66% above the current stock price
Dividend—
Payout ratio—
Earnings date2026-11-05
P/E2.43
Future P/E—
EPS (ttm)2.65
EPS growth next 5 years32.54%

As of Nov 5, 2026

Browse all Option Chain tickers